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Background: The diagnosis and staging of hilar cholangiocarcinoma (HCCA) remain challenging despite
recent advances in imaging. Little is known about the use of positron emission tomography/computed
tomography (PET/CT) in HCCA.
Objectives: This study aimed to evaluate the additional value of FDG-PET/CT and standardized uptake
value (SUV) in patients with highly suspected HCCA.
Methods: Between February 2006 and August 2009, PET/CT was performed in 30 patients with highly
suspected HCCA, all of whom were deemed resectable by conventional staging methods, including
laparoscopy. The results of PET-CT and SUV were compared with intraoperative and histopathological
findings.
Results: The primary tumour was 18F-FDG-positive in 88% of patients. Sensitivity and specificity for the
detection of regional lymph node metastases and distant metastases were 67% and 68%, and 33% and
96%, respectively. The median SUV in the primary tumour was significantly (P < 0.05) higher in patients
with (mean: 8.9) than without (mean: 6.1) distant metastases. The SUV in patients with benign disease (n
= 4) showed a trend towards lower values than in patients with cholangiocarcinoma, although this was not
significant.
Conclusions: After conventional staging including diagnostic laparoscopy, the additional value of
PET/CT is limited. This somewhat disappointing finding may reflect the fact that extensive staging studies
were carried out prior to PET/CT. The SUV potentially predicts patients with distant metastases and may
differentiate between HCCA and benign lesions that mimic malignancies.
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Introduction
Hilar cholangiocarcinoma (HCCA) involving the hepatic duct
confluence, or Klatskin’s tumour, accounts for approximately
60–70% of all cholangiocarcinomas. Since Klatskin’s first report of
this tumour,1 many subsequent publications have dealt with its
diagnosis, staging, surgical management and prognosis. The only
curative therapy has remained margin-negative (R0) resection.
Prognosis has improved significantly, with 5-year survival
rates of 25–35%2–5 after resection, usually encompassing extended
liver resection. Although morbidity and mortality rates have
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dropped in recent years, reported mortality rates still range from
9% to 15%.2–5 Therefore, accurate tumour staging and assessment
of resectability are crucial in the selection of patients in whom
curative surgery is possible. In addition, the differentiation of
HCCA from benign lesions that mimic malignancies has proven a
difficult diagnostic problem. Several institutional reports have
found 10–15% of patients suspected for HCCA to have been
misdiagnosed on microscopic examination of the resection
specimen.6,7
Different imaging techniques are used in the staging of HCCA.
Although the quality of imaging has improved in recent years, a
significant number of patients are found to be unresectable during
laparotomy, despite extensive preoperative work.8 Of the patients
who are surgically explored, only 40–50% are ultimately resect-
able9 and R0 resection is reportedly achieved in 19–80% of
resected patients.2–5 Hence, after two decades of experience and
despite all the improvements in diagnostic imaging, the correct
diagnosis and staging of HCCA remain challenging.
As malignant cells usually show increased glucose metabolism,
positron emission tomography (PET) imaging with the tracer
[18F]-fluoro-2-deoxy-d-glucose (18F-FDG; FDG-PET) has been
developed to detect primary tumours and distant metastases. This
technique has been shown to be highly sensitive and specific for the
detection of distant metastases from various primary tumours.
More recently, improved computing abilities and technology have
enabled FDG-PET to be fusedwith computed tomography (CT) to
add precision anatomic and functional localization. The value of
PET/CT has been proven in the detection of unknown primary
tumours10 and in the detection of distant metastases in the staging
of pancreatic,11 oesophageal12 and colorectal13,14 cancer. The poten-
tial role of FDG-PET/CT in cholangiocarcinoma and, particularly,
HCCA has not been well established.
The purpose of this study was to evaluate in retrospect the
additional value of FDG-PET/CT in the diagnosis and staging of
HCCA in our institution.
Materials and methods
Patients
Thirty patients who underwent PET/CT followed by intraopera-
tive assessment and histological confirmation of HCCA between
February 2006 and August 2009 were included in this study. These
patients were among a consecutive series referred to the Academic
Medical Centre (AMC), University of Amsterdam, a tertiary refer-
ral centre, with the presumptive diagnosis of HCCA. The charac-
teristics of these patients are shown in Table 1. Their median age
was 62 years (range: 36–77 years). Fourteen patients (47%) were
men and 16 (53%) were women.
The preoperative workup of our HCCA patients prior to
explorative laparotomy included a contrast-enhanced CT, trans-
abdominal ultrasound with Doppler imaging, direct cholangiog-
raphy when available, and diagnostic laparoscopy. The PET-
CT method was added as a final non-invasive tool to exclude
unresectability.
Magnetic resonance imaging (MRI) was also performed in 34%
of patients. The Bismuth–Corlette classification was used to
describe the proximal extent of the tumour preoperatively. The
definitive preoperative classification is shown in Table 1.
All patients underwent endoscopic retrograde cholangiopan-
creatography (ERCP) or percutaneous transhepatic cholangiod-
rainage (PTCD) for diagnosis and subsequent biliary drainage
approximately 6 weeks prior to surgery. Preoperative radiotherapy
(3 ¥ 3.5 Gy) was given to prevent the implantation of metastases
by ERCP or PTCD.15 The size and function of the future remnant
liver were assessed preoperatively by CT volumetry16 and 99mTc-
mebrofenin hepatobiliary scintigraphy.17 Portal vein embolization
was performed in two patients with insufficient future remnant
liver volume to induce hypertrophy and to reduce the risk of
postoperative liver failure.18
Table 1 Clinicopathological characteristics of patients
Characteristics %
Total patients, n 30 100
Age, years
Median 62 –
Range 39–75 –
Gender, n
Male 14 47
Female 16 53
Bismuth classification (preoperative), n
I 4 13
II 2 7
IIIa 10 33
IIIb 8 27
IV 6 20
Resection, n 21 70
R0 resection 19 90
R1 resection 2 10
Unresectable, n 9a 30
Extended local tumour infiltration 3 10
Peritonitis carcinomatosa 4 13
Liver metastasis 3 10
Type of resection, n
Hilar resection and liver resection 17 81
Hilar resection only 4 19
Pathology, n
Malignant 26 87
Benign 4 13
Metastases, n
Lymph node 6 20
Peritonitis carcinomatosa 4 13
Liver 3a 10
aOne patient was diagnosed with peritoneal and liver metastases
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PET/CT
Patients were fasted for at least 6 h and were hydrated orally with
sugar-free liquids. Oral contrast (Telebrix 5%) was given, starting
75 min before scanning. Patients received an average of 250 MBq
of 18F-FDG i.v. after resting for 15 min in bed. PET/CT imaging
was performed 60 min after FDG injection on a Philips Gemini
TF scanner (Philips Research Eindhoven, Eindhoven, the Nether-
lands) using a combination of 16-slice spiral CT and full-ring
PET. The camera was calibrated according to the protocol for the
standardization of quantitative FDG whole-body PET studies in
the Netherlands.20 Whole-body coverage was performed with an
axial scan ranging from the base of the skull to the upper thighs.
Low-dose CT images were acquired in spiral mode at 670 mAs,
120 kV, a slice width of 5 mm and a table feed of 8 mm/gantry
rotation. Images were reconstructed in 2.4-mm increments. All
patients were scanned using a limited breath-hold technique to
avoid the misregistration of images in the area of the diaphragm.
The time to acquire a single bed position was set to 3 min. Images
obtained using PET were corrected for attenuation based on the
CT data.
Computed tomography and PET images acquired by this com-
bined imaging system were viewed in separate and fused modes
using the fusion software Hybrid Viewer (Hermes Medical Solu-
tions AB, Stockholm, Sweden) by a board-certified radiologist and
a board-certified nuclear medicine doctor in consensus. For this
retrospective analysis, images were re-evaluated by an experienced
nuclear medicine doctor (RJB) who was trained in multimodal
imaging and who was unaware of findings obtained using other
conventional modes of imaging. Tumour staging using the
PET/CT images was scored according to the revised Union for
International Cancer Control (UICC) criteria (6th edition) for
extrahepatic bile duct cancer.19 These findings were compared
with intraoperative findings and the results of pathological exami-
nation. The histology reports were used as the reference standard
for the diagnosis of the primary tumour, lymph node involvement
and distant metastases. Images were evaluated qualitatively for
regions of focally increased glucose metabolism, as well as quan-
titatively by determining the standardized uptake values (SUVs).
An increase in glucose uptake above the levels in the surrounding
tissue on qualitative analysis was considered suspicious for malig-
nancy. Lymph node and distant metastases with increased glucose
utilization were diagnosed positive for metastatic spread, even if
their short axis diameter measured <10 mm.
Surgical procedures
Diagnostic laparoscopy, exploratory laparotomy and subsequent
tumour resection were performed by a surgical team specializing
in hepatobiliary surgery. During laparotomy, the abdomen was
inspected for lymph node involvement distant to the liver hilum,
peritoneal seeding and other extrahepatic metastases. Suspicious
lesions were excised or biopsied and analysed by frozen-section
histology. In cases of extrahepatic metastases, no further surgical
intervention was performed. Radical resection of HCCA encom-
passed the excision of the liver hilum en-bloc with (extended)
hemihepatectomy including the caudate lobe, excision of the
portal vein bifurcation when involved and complete lym-
phadenectomy of the hepatoduodenal ligament. Massive involve-
ment of the main trunk of the portal vein and/or hepatic artery
was considered a contraindication for resection. For biliary recon-
struction, end-to-side anastomoses of the segmental ducts and a
Roux-en-Y jejeunal loop were constructed.3
In most patients with resectable tumours, lymph node status
was evaluated by dissecting the hepatoduodenal ligament and
excising the lymph nodes along the common hepatic artery and
coeliac axis. In patients who were found to be unresectable during
diagnostic laparoscopy or explorative laparotomy, not all lymph
nodes were sampled.
Statistical analysis
Sensitivity, specificity, positive (PPV) and negative (NPV) predic-
tive values and accuracy were calculated for the staging of primary
tumours, regional lymph node and distant metastases.
The SUV was expressed as the mean  standard error.
Independent-samples t-test was used to test the predictive value of
the SUV for American Joint Committee on Cancer (AJCC) cancer
stage, presence of positive lymph nodes, presence of distant
metastases, resectability and benign disease. P-values of <0.05
were considered statistically significant. Data were analysed using
spss Version 16.0 (SPSS, Inc., Chicago, IL, USA).
Results
Clinicopathological characteristics
Of the 30 patients included in this study, resection was undertaken
in 21 (70%). In 27 patients (90%) a biliary plastic stent had been
placed prior to the PET/CT. Hilar resection in combination with
(extended) hemihepatectomy was performed in 17 patients (81%
of all resections). In four of the 21 resected patients (19%), hilar
resection was performed locally without formal liver resection.
Final histology showed benign disease in four patients (19%)
characterized as IgG-4-associated sclerosing cholangitis (n = 2),
intraductal papillary mucinous tumour (n = 1) and chronic
inflammation (n = 1). In the remaining 17 patients with con-
firmed HCCA, a microscopically complete (R0) resection was
achieved in 15 patients (88%).
18F-FDG-PET/CT accuracy for primary tumour, lymph
node and distant metastases
Twenty-three of 26 (sensitivity: 88%) patients with confirmed
HCCA were correctly identified when PET/CT showed FDG
uptake in the hilar region, which was also visible on the non-
attenuation corrected images. No lesions were correctly identified
as benign on qualitative evaluation because the benign lesions also
showed uptake of FDG. Overall PPV, NPV and accuracy rates for
primary tumour detection, presence of positive lymph nodes and
distant metastases are shown in Table 2.
258 HPB
HPB 2011, 13, 256–262 © 2011 International Hepato-Pancreato-Biliary Association
Overall, pathological examination showed positive lymph
nodes in six of 30 patients (20%). Four of these were correctly
identified (sensitivity: 66%) on PET/CT. However, lymph node
status was not assessed in three patients scored as N1 on PET/CT
because other findings during surgery precluded resection. As
Table 3 shows, PET/CT seemed to have a higher sensitivity for the
detection of positive lymph nodes than regular CT, although an
adequate statistical comparison was not possible because of the
small numbers involved. Lymph nodes were not further defined
with respect to localization (within or beyond the hepatoduode-
nal ligament), also because of the small size of the sample.
Unknown metastases after initial staging were apparent in six
patients and correctly identified in only two. None of the four
patients with peritoneal deposits were diagnosed on the basis of
PET/CT. Of three patients with liver metastases, two were cor-
rectly detected by PET/CT. One of these patients was preopera-
tively biopsied and a liver metastasis was histologically confirmed
and laparotomy avoided. In the other patient with suspected liver
metastasis on CT, a biopsy was inconclusive. Consequently, the
patient was explored and the metastasis confirmed. PET/CT
missed a liver metastasis in the third patient harbouring a small
subcapsular liver lesion. In one patient a liver metastasis was sus-
pected on the basis of PET/CT, but final biopsy and histology
showed an inflammatory infiltrate. This represented the site of a
biopsy during diagnostic laparoscopy which had proven to be a
chronically dilated bile duct and was subsequently over-sutured.
Incidental PET/CT positive findings in two patients showed a
Whartin tumour which required further evaluation in one and
an adrenal cyst and diverticulitis without further therapeutic
consequences in the other.
SUVmax
Standardized uptake values and corresponding clinicopathologi-
cal characteristics are depicted in Table 4. The SUV showed no
significant predictive power for AJCC cancer stage, presence of
positive lymph nodes or resectability, but was significantly
higher in patients diagnosed with distant metastases (P = 0.02).
In addition, the SUV was lower in benign lesions, although the
difference was not statistically significant in this small group of
patients (P = 0.09).
Potential impact on management
If FDG-PET/CT had been used to restage patients after initial
staging including diagnostic laparoscopy, it would have changed
the management strategy applied in three of the 30 patients
(10%). Laparotomy might have been avoided in two patients with
liver metastases and additional imaging and treatment for a
Whartin tumour were required in one patient. Because of its
uncertain accuracy regarding lymph node staging, FDG-PET/CT
would not have changed the management of patients with nodal
disease. However, this may change when the accuracy of PET/CT
in lymph node staging is better defined.
Discussion
In this study of 30 patients with suspected HCCA considered for
curative surgery, the primary tumour was 18F-FDG-positive in
Table 2 Positron emission tomography/computed tomography results for primary tumour detection, positive lymph nodes and distant
metastases
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Primary tumour 23/26 (88) 0/4 (0) 23/27 (85) 0/3 (0) 23/30 (77)
Lymph nodes metastases 4/6 (67) 12/18 (67) 4/10 (40) 12/14 (86) 16/24 (67)
Distant metastases 2/6 (33) 23/24 (96) 2/3 (66) 23/27 (85) 25/30 (83)
PPV, positive predictive value; NPV, negative predictive value
Table 3 Comparison of regular computed tomography (CT) with
positron emission tomography/CT (PET/CT) for lymph node staging
CT PET/CT
Sensitivity 2/6 (33%) 4/6 (67%)
Specificity 12/18 (67%) 12/18 (67%)
Table 4 Standardized uptake value (SUV) and clinicopathological
factors in patients found positive for tumours on positron emission
tomography
Patients, n SUVmax
Mean  SE
P-value
N stagea
N0 12b 6.6  0.7 0.39
N1 6 5.7  0.7
M stagea
M0 18 6.1  0.5 0.02a
M1 5 8.9  1.1
AJCCa staging
Stage 1–2 5 7.5  1.3 0.44
Stage 3–4 18 6.5  0.6
Resectiona
R0 14 6.3  0.6 0.30
R1, no resection 9 7.4  0.9
Pathology
Benign 4 4.58  0.40 0.09
Malignant 23 6.7  0.50
aStandardized uptake values in patients with benign disease were
excluded
bN-stage was not assessed in six patients with unresectable disease
SE, standard error; AJCC, American Joint Committee on Cancer
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88% of cases. PET/CT correctly identified positive lymph nodes in
66% and distant metastases in 33% of patients.
Several studies have reported on the clinical usefulness of
PET/CT in HCCA in the last decade.21–25 However, as Table 5
shows, most series have pooled HCCA patients with those with
other cholangiocarcinomas, including gallbladder and intrahe-
patic cholangiocarcinomas. In these studies, patients with HCCA
often comprise only a minority of all included patients. Thus,
the differences in tumour biology, pattern and incidence of
metastases or the different types of cholangiocarcinoma make
the outcomes of these studies difficult to interpret. For example,
gallbladder cancer is known for its higher incidence of distant
metastases.
The 18F-FDG-positivity in 88% of patients found in this study is
high in comparison with rates reported elsewhere, as shown in
Table 5. However, this is of little relevance because our patients
were already diagnosed with HCCA based on clinical presenta-
tion, imaging studies and sometimes (brush) cytology. Moreover,
all benign lesions were also FDG-positive. Nonetheless, 18F-FDG-
positivity enables SUV measurements, which potentially facilitate
the differentiation of benign and malignant lesions.
The specificity found in this study to differentiate benign from
malignant lesions was low because all benign inflammatory
lesions showed increased FDG uptake and no true negative results
were found. This is compatible with the fact that most benign
lesions in the hilar liver region have an inflammatory origin,26 a
characteristic that is also known for increased metabolic activity
and FDG-PET-positivity. We therefore believe that qualitative
interpretation of PET/CT alone does not discriminate between
benign and malignant lesions in the hilar region, but that calcu-
lation of the SUVmay be of potential value in differentiating these
lesions, as shown in this study.
The detection of positive lymph nodes on CT images is pri-
marily based on lymph node size. Nodes of >10 mm in the
smallest diameter are suspicious. The sensitivity and specificity
of this size-based lymph node characterization are known to be
minimal and its clinical usefulness therefore remains limited.
The addition of 18F-FDG-PET/CT might potentially improve the
accuracy of lymph node staging. In this study, the accuracy of
PET/CT for lymph node staging seemed better than that of CT
alone. The accuracy of PET/CT may have been even better
because nodal status was not assessed in three patients with
PET-positive lymph nodes because these patients were not resec-
table. Clearly, numbers in this study are too small to allow for
adequate statistical evaluation and care must be taken not to
draw conclusions on these data. Lee et al. found statistical sig-
nificance only for specificity in favour of PET/CT for lymph
node staging in their relatively large series of extrahepatic cho-
langiocarcinomas.23 Hence, larger studies are needed to draw
definitive conclusions regarding the value of PET/CT in the
assessment of lymph node involvement.
The sensitivity of 33% for the detection of distant metastases in
this study was rather low, especially as this facility has been
thought to be the main advantage of PET/CT. However, the
metastases found had not been detected in the initial staging,
including diagnostic laparoscopy. The results were also inferior to
those of other studies, which reported detection rates of distant
metastases of 56–100%.21–25 These differences in rates may possi-
bly be explained by two factors. Firstly, distant metastases in our
study included mostly peritoneal metastases (66%), which are
hard to detect in PET/CT or other imaging modalities. Secondly,
this study included a selected group of patients who were consid-
ered to be eligible for curative surgery after exhaustive preopera-
tive workup, including diagnostic laparoscopy in all cases.
Consequently, the incidence of distant metastases was low and
only metastases which were small and difficult to diagnose were
featured in this study. Both PET/CT and diagnostic laparoscopy
are performed in order to exclude metastases. Given the invasive-
ness of diagnostic laparoscopy and its accompanying morbidity
and length of hospital stay, the potential contribution of PET/CT
to reducing the number of patients undergoing this procedure
may be beneficial.
The calculated SUVs for the primary tumour and metastatic
lesions showed promising results. Patients with distant metastases
had significantly higher SUVs for the primary tumour. This may
be secondary to the higher tumourmetabolism of more aggressive
Table 5 Studies reporting on positron emission tomography/computed tomography and hilar cholangiocarcinoma (HCCA)
Author HCCA patients/total
patients, n/n
Primary tumour detection Positive lymph node
detection
Distant metastases
detection
Petrowsky et al. (2006)25 20/60 55%a 12%c 100%
Jadvar et al. (2007)21 NR 94%b NR 100%
Li et al. (2008)24 17/17 59% 42% 56%
Kim et al. (2008)28 37/123 81%a 32%a 58%c
Lee et al. (2009)23 49a/99 84%a 82%a 95%c
Present series 30/30 88% 66% 33%
aExtrahepatic cholangiocarcinomas, HCCA not specified
bKnown or suspected recurrent and metastatic cholangiocarcinomas
cIn all cholangiocarcinomas
NR, not reported
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primary lesions, which increases the likelihood of distant
metastases. Although this finding may not seem clinically useful at
this point, it may prove useful in selecting patients for diagnostic
laparoscopy.
Patients with benign disease seemed to have lower SUVs for
the primary lesion, although significance was not reached in this
small patient group. The latter findings were also reported by
Reinhardt et al., who determined an SUV of 3.6 as an ideal cut-
off point to discriminate between benign disease and cholang-
iocarcinoma.27 As absolute SUVs are known to vary between
centres, local recalibration is necessary to enable interpretation
of these results.20
There are several limitations to this retrospective study, which
aimed to assess the additional value of PET/CT as a final non-
invasive tool to help avoid unnecessary surgery in inoperable
patients. Because of the rarity of the disease, data were obtained
from a small group of patients in a retrospective manner, which
has inherent methodological drawbacks. Most HCCA patients
are referred to our tertiary hospital with a stent already in situ.
The insertion of such stents is frequently followed by an inflam-
matory reaction, which hampers the optimal interpretation of
PET/CT images. Therefore, we believe PET/CT should optimally
be performed prior to any invasive technique, including stent
placement and laparoscopy. Moreover, benign lesions of inflam-
matory origin mimicking malignancy occur in this patient group
and are a known source of false positive PET/CT readings.
Hence, any conclusions must be drawn with care. A prospective
study on a larger scale should be conducted to confirm these
results and to further define the role of PET/CT in the staging of
patients with HCCA.
Finally, by contrast with earlier studies,21,23–25,28 the yield of
PET/CT after intensive staging was rather disappointing, given its
low sensitivity for detecting metastases and benign lesions, which
resulted in false positive PET/CT readings. This probably reflects
both the extensive staging carried out prior to PET/CT and the
high proportion of patients with peritoneal metastases. It is pos-
sible that the impact of PET/CT will improve when the technique
is used earlier in the staging process, especially before invasive
procedures such as diagnostic laparoscopy are undertaken. By
contrast, SUVs showed promising results for predicting
metastases. Further research is warranted to confirm these results
and to identify certain cut-off values to make the assessment of
SUVs useful in a clinical setting (i.e. for selecting patients for
diagnostic laparoscopy and possibly neoadjuvant therapy).
In conclusion, after conventional staging including diagnostic
laparoscopy, the additional value of PET/CT is limited. This some-
what disappointing findingmay possibly reflect a context in which
extensive staging studies have been carried out prior to PET/CT,
whereas the yield of PET/CT may be higher if it is conducted
before any invasive procedures. In addition to qualitative (visual)
interpretation of images, SUV calculation potentially predicts
patients with distant metastases and may differentiate between
HCCA and benign lesions that mimic malignancies.
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